(19) World Intellectual Property Organization

International Bureau



- | 1881 | 1 | 1881 | 1 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 |

(43) International Publication Date 4 August 2005 (04.08.2005)

PCT

(10) International Publication Number WO 2005/070902 A1

- (51) International Patent Classification: C07D 239/84, 401/12, 403/12, 409/12, A61K 31/517, A61P 3/04, 25/18, 25/28
- (21) International Application Number:

PCT/SE2005/000010

- (22) International Filing Date: 5 January 2005 (05.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

0400193.9 7 January 2004 (07.01.2004) GB

- (71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EVERTSSON, Emma [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). INGHARDT, Tord [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINDBERG, Jan [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINUSSON, Anna [SE/SE]; Umeå University, Organic Chemistry, S-901 87 Umeå (SE).
- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC AGENTS II

$$(R^{1})_{n} = \begin{pmatrix} R^{2} & & & \\ & & & \\ & & & \\ N & & & \\ N & & & \\ N & & & \\ & & & \\ R^{3} & & & \\ & & & \\ & & & \\ \end{pmatrix}_{1}^{N} = L^{1} - N - L^{2} - R^{5}$$
 (I)

(57) Abstract: Compounds of Formula (I) as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.